Pseudomembranous Invasive Tracheobronchial Aspergillosis with Fulminant Hepatitis and Hemophagocytic Syndrome

Suguru Majima¹, Shotaro Okachi¹, Motoyo Asano³, Keiko Wakahara¹, Naozumi Hashimoto¹, Mitsuo Sato¹, Masatoshi Ishigami³ and Yoshinori Hasegawa¹

Abstract:
Invasive tracheobronchial aspergillosis (ITBA), a rare form of invasive pulmonary Aspergillus infection (IPA), is predominantly confined to the tracheobronchial tree. We herein report a case of ITBA with severe necrotic pseudomembrane in a 57-year-old woman with fulminant hepatitis and hemophagocytic syndrome. Bronchoscopic findings revealed a widespread pseudomembranous formation of the trachea and bronchi. Aspergillus fumigatus was cultured from bronchial lavage fluid, and the histological findings of an endobronchial biopsy revealed necrosis and invasive hyphae. Although she responded to antifungal treatment, she ultimately died of a septic shock with Burkholderia cepacia 57 days after admission.

Key words: invasive tracheobronchial aspergillosis, fulminant hepatitis, hemophagocytic syndrome, bronchoscopy

(Intern Med 57: 2371-2375, 2018)
(DOI: 10.2169/internalmedicine.9673-17)

Introduction
Invasive tracheobronchial aspergillosis (ITBA), a rare form of invasive Aspergillus infection, is mainly restricted to tracheobronchial lesions (1). It primarily occurs in immunocompromised hosts, such as patients receiving solid organ transplant, patients with hematologic malignancies, or patients undergoing immunosuppressive therapy, including corticosteroid therapy (2-4). Three different forms of ITBA have been described on the basis of the bronchoscopic or pathologic appearance: Aspergillus tracheobronchitis, ulcerative Aspergillus tracheobronchitis, and pseudomembranous Aspergillus tracheobronchitis (5). Li et al. suggested that pseudomembranous ITBA potentially followed an aggressive course with the rapid progression of lung parenchymal involvement and a fatal outcome, even in immunocompetent patients (6).

We herein report a rare case of whole-circumference pseudomembranous ITBA with fulminant hepatitis (FH) and hemophagocytic syndrome (HPS).

Case Report
A 57-year-old woman with no significant medical history of the habitual use of alcohol, tobacco, or diet supplements suffered from a fever and diarrhea. Following the ingestion of tetracycline as prescribed by a family doctor, she felt fatigue and was admitted to a local general hospital. The laboratory findings revealed elevated transaminase levels [aspartate aminotransferase (AST), 5,255 IU/L; alanine aminotransferase (ALT), 2,435 IU/L], bicytopenia (leukocytes, 1,200/μL; polymorphonuclear neutrophils, 36.3%; atypical lymphocytes, 24%; and platelets, 5.0×10⁴/μL), and a reduced prothrombin time (PT) activity, 36.3%. Her hepatitis A virus-specific IgM antibodies (HAV-IgM), hepatitis B surface (HBs) antigen, hepatitis C virus (HCV) antibody, viral capsid antigen (VCM)-IGM, cytomegalovirus (CMV) antigenemia, antimitochondrial antibody (AMA), anti-smooth muscle antibody (ASMA), HTLV-1 antibody, and HIV antibody findings were negative. She subsequently demonstrated signs of encephalopathy in the form of confusion and slow
A bone marrow biopsy revealed increased numbers of maturity histiocytes with significant hemophagocytosis. She was subsequently diagnosed with FH and HPS. Although she underwent steroid pulse therapy and continuous hemodiafiltration (CHDF), her condition did not improve. Therefore, she was transferred to our hospital for treatment, including liver transplantation.

Three days after admission, she developed severe respiratory failure and underwent tracheal intubation for mechanical ventilation. Computed tomography (CT) of the chest revealed bronchial wall thickening and bilateral diffuse infiltration shadow of lungs (Fig. 1). The bronchosscopic findings revealed a widespread pseudomembranous formation covering the entire circumference of the trachea and bronchi (Fig. 2). In addition, the β-D-glucan level was significantly increased to 617 pg/dL, and the *Aspergillus* galactomannan antigen level (ELISA) was >5.0. Other laboratory findings revealed C-reactive protein (CRP) at 2.52 mg/dL and procalcitonin (PCT) at 0.4 ng/mL (Table). The findings from a blood gas test were as follows: pH 7.32; PaO₂, 89.4 mmHg; PaCO₂, 40.6 mmHg; HCO₃⁻, 19.3 mmol/L; and PaO₂/FiO₂, 149. Furthermore, an endobronchial biopsy under bronchoscopy revealed active inflammation with necrotic tissue and numerous filamentous fungal hyphae infiltration in all layers (except for some parts of the gland duct structure and cartilage tissue) (Fig. 3). *Aspergillus fumigatus* and *Burkholderia cepacia* were isolated from bronchial lavage fluid cultures. She was therefore diagnosed with pseudomembranous ITBA and acute respiratory distress syndrome (ARDS). Possible causes of the diffuse infiltration shadow of the lungs included bacterial pneumonia, invasive pulmonary aspergillosis (IPA), and pulmonary edema; however, we were unable to perform bronchoalveolar lavage (BAL) because of severe respiratory failure.

The patient received broad-spectrum antibiotics (imipenem) and antifungal therapy with intravenous voriconazole (200 mg/day) and caspofungin (35 mg/day). The β-D-glucan level decreased over time, and the tracheobronchial pseudomembrane showed scarring on reexamination.
Figure 2. Bronchoscopic findings revealed a widespread pseudomembranous formation covering the entire circumference of the trachea (A) and right main bronchus (B).

Figure 3. Photomicrograph of the biopsy specimen from the trachea showed active inflammation with necrotic tissue and numerous filamentous fungal hyphae infiltration at all layers of tissue (Hematoxylin and Eosin staining ×100).

Discussion

ITBA is relatively rare and is seen in less than 10% of IPA cases (7). Reported comorbidities with ITBA include solid organ transplantation, hematologic malignancies, or HIV infection. In a case series and review, most patients (86.5%) had some degree of immunosuppression, including long-term corticosteroid therapy (71.8%), active chemotherapy (25.0%), or neutropenia (18.7%) (7). However, the patient in the present case had no chronic immunosuppressive disease as described above. One case report describes a patient who developed ITBA following infection of influenza without a chronic immunosuppressive state (8). Although previous reports of ITBA with liver disease mainly describe patients undergoing liver transplantation, Marco et al. reported that patients with advanced or acute liver disease had an increased susceptibility to fungal infections due to the impairment of neutrophil immune mechanisms, the frequent use of corticosteroids, and malnutrition. The report also revealed that the mortality rate for invasive aspergillosis in patients with severe liver disease was as high as 70% (9). Lawrence et al. reported a case of IPA complicated with HPS (10).

There are many causes of FH, including viral infection, autoimmune hepatitis, and drug-related hepatitis (11). The etiology in the present case was likely drug-related (tetracycline), as almost all of the virological tests (HAV, HBV, HCV, CMV, or EBV) and immunological tests (ANA, AMA, or ASMA) were negative. In addition, there have been some reports of drug-induced acute hepatic failure associated with tetracycline (12-14).

Bronchoscopic procedures, such as BAL and transbronchial biopsies, are very useful for the diagnosis of IPA (15). Moçin et al. reported that the sensitivity, specificity, and positive and negative predictive values of BAL for the diagnosis of tracheobronchial fungal infection were 85.1%, 81.4%, 66.3%, and 92.7%, respectively, and 35% of patients who underwent biopsies were confirmed to have fungal elements (16). Aspergillus fumigatus is the most common species in patients with tracheobronchial involvement. Karnak et al. reviewed 121 cases of endobronchial aspergillosis and found that 63% of patients with tracheobronchial infections had Aspergillus fumigatus, just as in this case (17).

ITBA is classified into three subtypes based on the bronchoscopic and/or pathologic features: Aspergillus tracheobronchitis, ulcerative Aspergillus tracheobronchitis, and pseudomembranous Aspergillus tracheobronchitis (5). Pseudomembranous Aspergillus tracheobronchitis is characterized by pseudomembranes coating the mucosal surface of the tracheobronchial tree. The present case in particular showed a significant pseudomembranous mucosal surface with whitish plaques covering the entire circumference from the trachea to bronchi. This case is also rare in terms of the severe en-
scopic findings compared with previous reports of ITBA (18). Although Staphylococcus aureus, Bacillus cereus, Streptococcus pyogenes, and nondiphtherial corynebacteria have also been reported as differential causative pathogens of pseudomembranous tracheobronchitis, Aspergillus spp. is the most common organism inducing pseudomembranous tracheobronchitis (19-23).

In lung transplant patients, the mortality ratio of ITBA reportedly ranges from 14-23.7% (24-26). The prognosis in severely immunocompromised patients with hematological malignancies and ITBA is significantly worse than that of ITBA with other diseases. Tasci et al. reported that no patients with hematological malignancies with ITBA survived (18). Krenke et al. conducted a review and reported that the mortality rate related to Aspergillus infection with hematological malignancies was as high as 72.2% (27), although several reports have suggested a better prognosis in patients with ITBA without malignant disease, with only 1 in 5 reported patients dying (mortality rate 20%) (28, 29). In their multivariate logistic regression analysis, Fernández et al. found that the presence of neutropenia [odds ratio (OR), 20.47; 95% confidence interval (CI), 3.92-106.94; p=0.001] and acute respiratory distress at presentation (OR, 9.54; 95% CI, 2.27-40.05; p=0.002) were independent prognostic factors for the in-hospital mortality rate of Aspergillus tracheobronchitis (7). In the present case, both acute respiratory distress and neutropenia were applicable as prognostic factors.

The latest Infectious Diseases Society of America (IDSA) guidelines recommend voriconazole for the primary treatment of IPA (30). Alternative therapies include liposomal amphotericin (AmB), isavuconazole, or other lipid formulations of AmB. The combination of antifungal therapy with voriconazole and echinocandins may be considered in select patients with documented IPA. Fernández et al. reported combination therapy with trizole or AmB plus nebulized AmB (n-AmB) as the initial treatment for ITBA (7). The IDSA guidelines recommend the use of an inhaled AmB as well as a systemic triazole for antifungal prophylaxis in lung transplant recipients, however, the effectiveness of inhaled antifungal therapy for ITBA in immunosuppressed patients remains to be elucidated (30).

We administered combination therapy with voriconazole and caspofungin in the present patient because of her severe status. While the antifungal therapy was deemed effective, resulting in reduced β-D-glucan levels and positive changes in the tracheal bronchus mucosa on follow-up bronchoscopy, the patient ultimately died of septic shock and respiratory failure.

In conclusion, we reported a unique case of whole-circumference pseudomembranous ITBA without organ transplantation or malignancy that followed a fatal clinical course.

The authors state that they have no Conflict of Interest (COI).

References

1. Kemper CA, Hostetter JS, Follansbee SE, et al. Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. Clin Infect Dis 17: 344-352, 1993.
2. Chang SM, Kuo HT, Lin PJ, Tzen CY, Sheu CY. Pseudomembranous tracheobronchitis caused by Aspergillus in immunocompromised patients. Scandi J Infect Dis 37: 937-942, 2005.
3. Franco J, Munoz C, Vila B, Marin J. Pseudomembranous invasive tracheobronchial aspergillosis. Thorax 59: 452, 2004.
4. Mohan A, Guleria R, Das C, Sharma SK, Mukhopadhyaya S, Nayak A. Invasive tracheobronchial aspergillosis in an immunocompetent person. Am J Med Sci 329: 107-109, 2005.
5. Kramer MR, Denning DW, Marshall SE, et al. Ulcerative tracheobronchitis after lung transplantation: a new form of invasive aspergillosis. Am Rev of Respir Dis 144: 552-556, 1991.
6. Li Y, Yu F, Parsons C, et al. Pseudomembranous Aspergillus tracheobronchitis: a potential for high mortality in low-risk patients. Am J Med Sci 346: 366-370, 2013.
7. Fernández-Ruiz M, Silva JT, San-Juan R, et al. Aspergillus tracheobronchitis report of 8 cases and review of the literature. Medic 91: 261-273, 2012.
8. Boots RJ, Paterson DL, Allworth AM, Foaagali JL. Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin B, gamma interferon and GM-CSF. Thorax 54: 1047-1049, 1999.
9. Falcone M, Massetti AP, Russo A, Vullo V, Venditti M. Invasive aspergillosis in patients with liver disease. Med Mycol 49: 406-413, 2011.
10. Tiemey LM Jr, Thabet A, Nishino H. Case 10-2011 - a woman with fever, confusion, liver failure, anemia, and thrombocytopenia. N Engl J Med 364: 1259-1270, 2011.
11. Ichi P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl 14(Suppl 2): 567-579, 2008.
12. Min DL, Burke PA, Lewis WD, Jenkins RL. Acute hepatic failure associated with oral minocycline: a case report. Pharmacotherapy 12: 68-71, 1992.
13. Lawsonson RA, Seaman HE, Sundström A, Williams TJ, Farmer RD. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf 23: 333-349, 2000.
14. Malcolm A, Haep TR, Eckstein RP, Lunzer MR. Minocycline-induced liver injury. Am J Gastroenterol 92: 1641-1643, 1996.
15. Blot SI, Taccone FS, Van den Abeele AM, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med 186: 56-64, 2012.
16. Yançoğlu Moçin Ö, Karakurt Z, Aksoy F, et al. Bronchoscopy as an indicator of tracheobronchial fungal infection in non-immunocompromised intensive-care unit patients. Clin Microbiol Infect 19: 136-141, 2013.
17. Karnak D, Avery RK, Gildea TR, Sahoo D, Mehta AC. Endobronchial fungal disease: an under-recognized entity. Respiration 74: 88-104, 2007.
18. Tasci S, Glassmacher A, Lentini S, et al. Pseudomembranous and obstructive Aspergillus tracheobronchitis-optimal diagnostic strategy and outcome. Mycoses 49: 37-42, 2006.
19. Park SS, Kim SH, Kim M, et al. A case of severe pseudomembranous tracheobronchitis complicated by co-infection of influenza A (H1N1) and staphylococcus aureus in an immunocompetent patient. Tuberc Respir Dis (Seoul) 78: 366-370, 2015.
20. Strauss R, Mueller A, Wehler M, et al. Pseudomembranous tracheobronchitis due to Bacillus cereus. Clin Infect Dis 33: 39-41, 2001.
21. Henderson MH, Spradley CD, DeKenatrty DR. Pseudomembranous tracheobronchitis due to Streptococcus pyogenes: a case report.

2374
22. Colt HG, Morris JF, Marston BJ, Sewell DL. Necrotizing tracheitis caused by Corynebacterium pseudodiphtheriticum: unique case and review. Rev Infect Dis 13: 73-76, 1991.

23. Al-Qadi MO, Artenstein AW, Baraman SS. The “forgotten zone”: acquired disorders of the trachea in adults. Respir Med 107: 1301-1313, 2013.

24. Mehrad B, Paciocco G, Martinez FJ, Ojo TC, Iannettoni MD, Lynch JP. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. CHEST J 119: 169-175, 2001.

25. Sole A, Morant P, Salavert M, Peman J, Morales P. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 11: 359-365, 2005.

26. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 22: 258-266, 2003.

27. Krenke R, Grabczak EM. Tracheobronchial manifestations of Aspergillus infections. Sci World J 11: 2310-2329, 2011.

28. Ramos A, Segovia J, Gómez-Bueno M, et al. Pseudomembranous Aspergillus tracheobronchitis in a heart transplant recipient. Transpl Infect Dis 12: 60-63, 2010.

29. Pornsuriyasak P, Murgu S, Colt H. Pseudomembranous Aspergillus tracheobronchitis superimposed on post-tuberculosis tracheal stenosis. Respirology 14: 144-147, 2009.

30. Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 63: 1-60, 2016.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).

© 2018 The Japanese Society of Internal Medicine

Intern Med 57: 2371-2375, 2018